Neurotrope announces board and management changes
Neurotrope announced it has reached a settlement agreement with Iroquois Master Fund Ltd. and certain of its affiliates, with regard to a proposed consent solicitation by Iroquois.
As part of the settlement, Paul E. Freiman and Jay M. Haft resigned from the Board of Directors.
The Board elected Joshua Silverman as chairman of the board and Kenneth J. Gorelick joins the board.
Dr. Gorelick is the Managing Director of Zymo Consulting Group LLC, that provides consulting services to the biopharmaceutical industry, specializing in clinical development and regulatory affairs.
He currently serves as Chair of the Program Advisory Board for Asahi Kasei Pharma America and as Chief Medical Officer for PIN Pharma, among others.
Dr. Gorelick received his MD from Cornell University, and post-doctoral training at St. Louis University and Stanford University where he was also a member of the clinical faculty.
Previously he was Vice President of Global Clinical Research and Development at DuPont Merck Pharmaceutical Company.
In addition, the Company’s Chief Executive Officer and President, Charles Ramat, entered into a Separation Agreement with the Company pursuant to which he shall remain on as a consultant and resign from the Board and all other positions that he holds with the Company, including Chief Executive Officer and President, on October 3, 2016 (unless the Board determines an earlier date).